Beth A. Morris
www.linkedin.com
0009-0006-4347-2042
Biohaven Pharmaceuticals (United States)
3 papers found
Refreshing results…
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
Missing publications? Search for publications with a matching author name.